Preferred Label : Trastuzumab Rezetecan;
NCIt synonyms : Anti-HER2 ADC BAT8001; ADC SHR-A1811; Anti-HER2 ADC SHR-A1811; Anti-HER2 Antibody-drug Conjugate SHR-A1811;
NCIt definition : An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin
G1-kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen
(TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to
rezetecan, which is composed of a cleavable linker and a camptothecin derivative,
with potential antineoplastic activity. Upon administration of trastuzumab rezetecan,
the trastuzumab moiety targets and binds to HER2 expressed on tumor cells. Upon cellular
uptake and linker cleavage, the camptothecin derivative stabilizes covalent topoisomerase
I-DNA complexes, and results in single-stranded and double-stranded DNA breaks, the
inhibition of DNA replication, the induction of apoptosis and the inhibition of tumor
cell proliferation in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor,
is overexpressed by many cancer cell types.;
UNII : 1000BJC8CR;
CAS number : 2647845-11-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2647845-11-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : SHR-A1811; SHR A1811;
NCI Metathesaurus CUI : CL1647822;
Origin ID : C178312;
UMLS CUI : C5706700;
Semantic type(s)
- concept_is_in_subset
- has_target
